The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy

NAUnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

June 30, 2010

Conditions
Laryngoscopy
Interventions
DRUG

remifentanil infusion

rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1

DRUG

rocuronium dose + remifentanil infusion

rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1

DRUG

rocuronium dose + remifentanil infusion

rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1

DRUG

remifentanil infusion

rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1

DRUG

rocuronium dose + remifentanil infusion

rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1

DRUG

rocuronium dose + remifentanil infusion

rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1

Trial Locations (1)

10011

RECRUITING

Saint Vincent Catholic Medical Centers, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic - MITG

INDUSTRY

lead

St. Vincent's Medical Center

UNKNOWN

NCT00926718 - The Effect of Rocuronium on the Response of Composite Variability Index (CVI) to Laryngoscopy | Biotech Hunter | Biotech Hunter